What is Erenumab?

Category: Prescription Drugs

Most popular types: Aimovig

false

Erenumab is a preventative treatment for adults with migraines.

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Migraine 52 28
Status migrainosus 2 2
Cervical spondylosis 1 0
Headaches 1 1

  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 5
Moderate 3
Mild 10
None 10

Commonly reported side effects and conditions associated with Erenumab

Side effect Patients Percentage
Constipation 5
Chronic fatigue 1
Depressed mood 1
Dizziness 1
Fatigue 1
Functional constipation 1

Show all 12 reported side effects

Dosages

Based on patients currently taking Erenumab

Dosage Patients Percentage
140 mg monthly 5
70 mg monthly 1
70 mg every 3 weeks 1
4900 mg monthly 1

Why patients stopped taking Erenumab

Multiple reasons could be selected

Reason Patients Percentage
Did not seem to work 3
Side effects too severe 3
Other 2
Change in health plan coverage 1
Doctor's advice 1
See all 8 patients who've stopped taking Erenumab

Duration

Currently taking Erenumab

Duration Patients Percentage
1 - 6 months 2
6 months - 1 year 1
1 - 2 years 5

Stopped taking Erenumab

Duration Patients Percentage
Less than 1 month 1
1 - 6 months 3
6 months - 1 year 3
1 - 2 years 2
Adherence
Adherence Evaluations Percentage
Always 25
Usually 2
Sometimes 0
Never taken as prescribed 1
Burden
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 3
A little hard to take 5
Not at all hard to take 20
Cost per month
Cost per month Evaluations Percentage
$200+ 4
$100-199 1
$50-99 3
$25-49 3
< $25 13
Not specified 4

What people switch to and from

Patients started taking Erenumab after stopping:

Treatment Patients Percentage
Sumatriptan (Imitrex) 4
Botulinum Toxin Type A (Botox) 2
Gabapentin (Neurontin) 1
Naratriptan (Amerge) 1
Topiramate (Topamax) 1

Show all 6 treatments patients report switching from

Patients stopped taking Erenumab and switched to:

Treatment Patients Percentage
Fremanezumab (Ajovy) 3
galcanezumab-gnlm (Emgality) 3
Last updated:
There are no evaluations for Erenumab.